
HEARTio is an AI-powered diagnostic platform that diagnoses heart disease using a simple ECG in just 10 seconds, without new hardware, surgery, contrast, or radiation. The company aims to prevent heart attacks before they happen by empowering providers with instant detection of hidden heart disease. Their executive team includes Utkars Jain (CEO), Adam Butchy (CSO), and Michael Leasure (COO), supported by a strong advisory board of medical and industry experts. They have secured Series A funding led by Shepherd Ventures III. HEARTio is not FDA cleared or approved.

HEARTio is an AI-powered diagnostic platform that diagnoses heart disease using a simple ECG in just 10 seconds, without new hardware, surgery, contrast, or radiation. The company aims to prevent heart attacks before they happen by empowering providers with instant detection of hidden heart disease. Their executive team includes Utkars Jain (CEO), Adam Butchy (CSO), and Michael Leasure (COO), supported by a strong advisory board of medical and industry experts. They have secured Series A funding led by Shepherd Ventures III. HEARTio is not FDA cleared or approved.
What they do: AI software (ECGio) that analyzes standard 12‑lead ECGs to detect coronary artery disease and cardiac abnormalities
Founded / HQ: 2018; Pittsburgh, Pennsylvania
Founders / leadership: Founders: Adam Butchy, Utkars Jain, Michael Leasure; Executive team includes Utkars Jain (CEO), Adam Butchy (CSO), Michael Leasure (COO)
Funding to date: Approximately $1.5M (angel investments, grants, competition awards)
Regulatory status: Not FDA cleared or approved
Early detection and risk stratification of cardiovascular disease using ECG analysis.
2018
Biotechnology
Approximately $1.5M (cumulative)
Raised via mix of angel investments, foundation grants (including Richard King Mellon Foundation) and competition prizes
Crunchbase lists multiple early-stage rounds with latest disclosed round as Pre-Seed
“Creative Destruction Lab (CDL)”